Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Oscar Camacho
Observed names:
O. Camacho,
Óscar Camacho
Institution:
Hospital de Sant Joan Despí Moisès Broggi
Observed institutions:
Consejo Superior de Investigaciones Científicas,
Hospital Clínic de Barcelona,
Institute of Advanced Chemistry of Catalonia,
Hospital de Sant Joan Despí Moisès Broggi
ORCID:
0000-0002-4347-3401
Observed ORCID:
0000-0002-4347-3401
OpenAlex ID:
A5020850826
Rheumatoid Arthritis Initiating as Palindromic Rheumatism: A Distinct Clinical Phenotype?
2019
·
Raul Castellanos-Moreira
, Sebastian C. Rodriguez-Garcia
, et al.
·
The Journal of Rheumatology
·
16
PDF
Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial
2026
·
Raimon Sanmarti
, Carolina Pérez-García
, et al.
·
Nature Medicine
·
2
PDF
Active hand inflammation. Differing clinical and ultrasound patterns in patients with rheumatoid arthritis and psoriatic arthritis – A cross-sectional, multicenter study
2025
·
Julio Ramírez
, Vicenç Torrente-Segarra
, et al.
·
Joint Bone Spine
·
2
AB0332 Comorbidities prevalence and charlson index in a cohort of patients with rheumatoid arthritis
2018
·
A.B. Azuaga-Piñango
, R. Castellanos-Moreira
, et al.
·
Annals of the Rheumatic Diseases
·
2
PDF
AB0466 Safety of rituximab in patients with rheumatoid arthritis. eleven-year follow-up observational study
2018
·
S.D.L.C. Rodriguez García
, R. Castellanos-Moreira
, et al.
·
Annals of the Rheumatic Diseases
·
2
PDF
Prognostic value of quantifying vascular inflammation through ultrasound in patients with giant cell arteritis: the MAGiCUS study
2026
·
Juan Molina-Collada
, Sharon Cowley
, et al.
·
Rheumatology
·
1
THU0090 Prevalence and clinical phenotype of anti-carbamylated protein antibodies in palindromic rheumatism
2018
·
R. Castellanos-Moreira
, S. Cabrera-Villalba
, et al.
·
Annals of the Rheumatic Diseases
·
1
PDF
POS0611 ONE YEAR PERSISTENCE AND EFFECTIVENESS OF GUSELKUMAB OR TNFi AS SECOND-LINE TREATMENT AFTER RECEIVING A TNFi AS FIRST-LINE THERAPY TO TREAT ACTIVE PSORIATIC ARTHRITIS: MANHATTAN STUDY
2025
·
B. Joven-Ibáñez
, M.R. Gonzalez Molina
, et al.
·
Annals of the Rheumatic Diseases
Abs0878 Interstitial Lung Disease in Primary Sjögren Syndrome: Pathochrony, Seronegative Cases, and Risk of Progressive Pulmonary Fibrosis
2025
·
D. Reina
, P. Estrada
, et al.
·
Annals of the Rheumatic Diseases
Thu0068 Anti-carbamylated Antibodies Are Associated With Tobacco and Poor Outcomes in Rheumatoid Arthritis
2019
·
Raul Castellanos-Moreira
, Sebastian C Rodriguez-García
, et al.
·
Annals of the Rheumatic Diseases
PDF
AB0395 Correlation between cardiovascular risk calculators in a cohort of patients with rheumatoid arthritis
2018
·
R. Castellanos-Moreira
, S.C. Rodriguez-Garcia
, et al.
·
Annals of the Rheumatic Diseases
PDF
AB0467 Sustained clinical response in refractory rheumatoid arthritis patients with a low-dose rituximab retreatment regimen
2018
·
S.D.L.C. Rodriguez García
, R. Castellanos-Moreira
, et al.
·
Annals of the Rheumatic Diseases
PDF
Show more works
View as search
Works count:
12
Citation count:
26
H-index:
2
I10-index:
1
Year
Topic
Type